Cited by 3,066Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Open access

Inzucchi, Silvio E., Bergenstal, Richard M., Buse, John B., Diamant, Michaela, Ferrannini, Ele, Nauck, Michael, Peters, Anne L., Tsapas, Apostolos, Wender, Richard, Matthews, David R.·2015·Diabetes Care

DOI 10.2337/dc14-2441

Open this paper in CoChat — free account

Abstract

In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. Between June and September of 2014, the Writing Group reconvened, including one face-to-face meeting, to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account (1,2). Glucose control remains a major focus in the management of patients with type 2 diabetes. However, this should always be in the context of a comprehensive cardiovascular risk factor reduction program, to include smoking cessation and the adoption of other healthy lifestyle habits, blood pressure control, lipid management with priority to statin medications, and, in some circumstances, antiplatelet therapy. Studies have conclusively determined that reducing hyperglycemia decreases the onset and progression of …

Integrity signals

Registry

Crossref · 10.2337/dc14-2441

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citation
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citation
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citation
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citation

Flagged first, then by citations

Show all 68 references

3 of the 68 references couldn’t be matched to a known paper.

Sorted by citations

Items 701–800 of 1,014

Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis
Men, P., He, N., Song, C., & Zhai, S. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.013 · Cited by 38
Diabetes and Hyperglycemia in Lower-Extremity Total Joint Arthroplasty
Rudy, M. D., Ahuja, N. K., & Aaronson, A. J. (2018) · JBJS Reviews · doi:10.2106/jbjs.rvw.17.00146 · Cited by 38
Combination urate-lowering therapy in the treatment of gout: What is the evidence?
Pérez-Ruiz, F., & Dalbeth, N. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.06.004 · Cited by 38
Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
Persson, F., Bodegård, J., Lahtela, J. T., Nyström, T., Jørgensen, M. E., Jensen, M. L., Gulseth, H. L., Thuresson, M., Hoti, F. J., Nathanson, D., et al. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.36 · Cited by 38
Stacked classifiers for individualized prediction of glycemic control following initiation of metformin therapy in type 2 diabetes
Murphree, D. H., Arabmakki, E., Ngufor, C. G., Storlie, C. B., & McCoy, R. G. (2018) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2018.10.017 · Cited by 39
Metformin and tenovin‐6 synergistically induces apoptosis through LKB1‐independent SIRT1 down‐regulation in non‐small cell lung cancer cells
Lee, B. B., Kim, Y., Kim, D., Cho, E. Y., Han, J., Kim, H. K., Shim, Y. M., & Kim, D. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14194 · Cited by 38
Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people
Hambling, C. E., Khunti, K., Cos, X., Wens, J., Martinez, L., Topsever, P., Prato, S. D., Sinclair, A. J., Schernthaner, G., Rutten, G. E. H. M., et al. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2018.12.005 · Cited by 38
The Effects of Mental Stress on Non-insulin-dependent Diabetes: Determining the Relationship Between Catecholamine and Adrenergic Signals from Stress, Anxiety, and Depression on the Physiological Changes in the Pancreatic Hormone Secretion
Wong, H., Singh, J., Go, R. M., Ahluwalia, N., & Guerrero-Go, M. A. (2019) · Cureus · doi:10.7759/cureus.5474 · Cited by 38
Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice
Shah, N. Z., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211042145 · Cited by 39
HbA1c below 7 % as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis
Wang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 38
Pharmacotherapy of ‘treatment resistant’ type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297424 · Cited by 38
Hypoglycemic and Hypolipidemic Effects of Leucine, Zinc, and Chromium, Alone and in Combination, in Rats with Type 2 Diabetes
Sadri, H., Larki, N. N., & Kolahian, S. (2017) · Biological Trace Element Research · doi:10.1007/s12011-017-1014-2 · Cited by 38
Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes
Chow, L. S., Zmora, R., Ma, S., Seaquist, E. R., & Schreiner, P. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000527 · Cited by 37
Diabetes self-management education and medical nutrition therapy improve patient outcomes: a pilot study documenting the efficacy of registered dietitian nutritionist interventions through retrospective chart review
Marincic, P. Z., Hardin, A., Salazar, M. V., Scott, S., Fan, S. X., & Gaillard, P. R. (2017) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2017.01.023 · Cited by 37
Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
Federici, M. O., McQuillan, J., Biricolti, G., Losi, S., Lebrec, J., Richards, C., Miglio, C., & Norrbacka, K. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0396-2 · Cited by 37
Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.
Villadolid, J. J., Ersek, J. L., Fong, M. K., Sirianno, L., & Story, E. S. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.10.01 · Cited by 37
Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573564 · Cited by 37
Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort
on behalf of the GCKD Study Investigators, Busch, M., Nadal, J., Schmid, M. C., Paul, K., Titze, S. I., Hübner, S., Köttgen, A., Schultheiß, U. T., Baid‐Agrawal, S., et al. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0273-z · Cited by 37
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers
Kuritzky, L., Reid, T., & Wysham, C. (2019) · Clinical Diabetes · doi:10.2337/cd18-0091 · Cited by 37
Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific Insulin Sensitivity
Makarova, E., Makrecka‐Kuka, M., Vilks, K., Volska, K., Sevostjanovs, E., Grīnberga, S., Zharkova‐Malkova, O., Dambrova, M., & Liepinsh, E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00870 · Cited by 37
Biosynthetic Human Insulin and Insulin Analogs
Rodbard, H. W., & Rodbard, D. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001089 · Cited by 37
Living with diabetes: literature review and secondary analysis of qualitative data
Stuckey, H. L., & Peyrot, M. F. (2020) · Diabetic Medicine · doi:10.1111/dme.14255 · Cited by 37
The consumption of sea buckthorn (Hippophae rhamnoides L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats
Dupák, R., Hrnkova, J., Šimonová, N., Kováč, J., Ivanišová, E., Kalafová, A., Schneidgenová, M., Prnová, M. Š., Brindza, J., Tokárová, K., et al. (2022) · Research in Veterinary Science · doi:10.1016/j.rvsc.2022.08.022 · Cited by 37
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 37
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial
Zang, L., Liu, Y., Geng, J., Luo, Y. M., Bian, F., Lv, X., Yang, J., Liu, J., Peng, Y., Li, Y., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12674 · Cited by 37
mHealth for diabetes self-management in the Kingdom of Saudi Arabia: barriers and solutions
Alanzi, T. M. (2018) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s174198 · Cited by 37
High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist
Ma, B., Wang, X., Ren, H., Li, Y., Zhang, H., Yang, M., & Li, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11077-w · Cited by 36
Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study
Iemitsu, K., Iizuka, T., Takihata, M., Takai, M., Nakajima, S., Minami, N., Umezawa, S., Kanamori, A., Takeda, H., Kawata, T., et al. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2492w · Cited by 36
Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once‐weekly dulaglutide treatment
Umpierrez, G. E., Pantalone, K. M., Kwan, A. Y. M., Zimmermann, A. G., Zhang, N., & Landó, L. F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12660 · Cited by 36
Detecting people at high risk of type 2 diabetes- How do we find them and who should be treated?
Kong, A. P. S., Luk, A. O. Y., & Chan, J. C. N. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.003 · Cited by 36
Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer
Rathmann, W., & Kostev, K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.012 · Cited by 36
Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization
Dalal, M. R., Kazemi, M. R., Ye, F., & Xie, L. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0592-x · Cited by 36
Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis
Ikeda, Y., Kubo, T., Oda, E., Abe, M., & Tokita, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12778 · Cited by 36
Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes
Laiteerapong, N., Cooper, J. M., Skandari, M. R., Clarke, P., Winn, A. N., Naylor, R. N., & Huang, E. S. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0537 · Cited by 36
The Role of Gut Microbiota in High-Fat-Diet-Induced Diabetes: Lessons from Animal Models and Humans
Qi, Y., & Wang, X. (2023) · Nutrients · doi:10.3390/nu15040922 · Cited by 37
What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences
Mühlbacher, A. C., & Bethge, S. (2015) · The European Journal of Health Economics · doi:10.1007/s10198-015-0750-5 · Cited by 36
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Divino, V. M., DeKoven, M., Khan, F. A., Boye, K. S., Sapin, H., & Norrbacka, K. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0224-5 · Cited by 36
Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers
Tong, L., & Adler, S. G. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457397 · Cited by 36
Self-Compassion, Metabolic Control and Health Status in Individuals with Type 2 Diabetes: A UK Observational Study
Morrison, A., Zaccardi, F., Chatterjee, S., Brady, E. M., Doherty, Y., Robertson, N., Hadjiconstantinou, M., Daniels, L. J., Hall, A. P., Khunti, K., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0897-3772 · Cited by 36
Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes
Matthews, D., Del Prato, S., Mohan, V., Mathieu, C., Vencio, S., Chan, J. C. N., Stumvoll, M., & Paldánius, P. M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00926-7 · Cited by 35
Self-citation
The effect of saffron (Crocus sativus L.) on glycemia, lipid profile, and antioxidant status in patients with type‐2 diabetes mellitus: A randomized placebo‐controlled trial
Tajaddini, A., Roshanravan, N., Mobasseri, M., Al‐qaim, Z. H., Hadi, A., Aeinehchi, A., Azar, P. S., & Ostadrahimi, A. (2022) · Phytotherapy Research · doi:10.1002/ptr.7600 · Cited by 35
Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
Lovshin, J. A., & Gilbert, R. E. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0551-3 · Cited by 35
Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus
Blair, H. A., & Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0541-z · Cited by 35
Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes
Anyanwagu, U., Mamza, J., Mehta, R. L., Donnelly, R., & IDRIS, I. R. (2016) · Heart · doi:10.1136/heartjnl-2015-309164 · Cited by 35
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes ( LIRA‐SWITCH ): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial
Bailey, T. S., Takács, R., Tinahones, F. J., Rao, P. V., Tsoukas, G. M., Thomsen, A. B., Kaltoft, M. S., & Maislos, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12736 · Cited by 35
Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study
Qin, L., Chen, S., Flood, E. M., Shaunik, A., Romero, B., de la Cruz, M., Alvarez, C., & Grandy, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0230-2 · Cited by 35
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s126763 · Cited by 35
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
Valentine, V., Goldman, J. D., & Shubrook, J. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0287-y · Cited by 35
Minimally Disruptive Medicine for Patients with Diabetes
Serrano, V., Spencer‐Bonilla, G., Boehmer, K. R., & Montori, V. M. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0935-7 · Cited by 35
Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes
Bauduceau, B., Floch, J. P. L., Halimi, S., Verny, C., Doucet, J., & Intergroup, T. S. (2017) · Diabetes Care · doi:10.2337/dc17-1437 · Cited by 35
Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs
Fei, Y., Tsoi, M. F., Kumana, C. R., Cheung, T. T., & Cheung, B. M. Y. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.039 · Cited by 35
Influence of gallic and tannic acid on therapeutic properties of acarbose in vitro and in vivo in Drosophila melanogaster
Oboh, G., Ogunsuyi, O. B., Adegbola, D. O., Ademiluyi, A. O., & Oladun, F. L. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.01.005 · Cited by 35
Advanced Nanoscale Build‐Up Sensors for Daily Life Monitoring of Diabetics
El‐Safty, S. A., & Shenashen, M. A. (2020) · Advanced Materials Interfaces · doi:10.1002/admi.202000153 · Cited by 35
In vitro antidiabetic potentials, antioxidant activities and phytochemical profile of african black pepper (Piper guineense)
Sulaimon, L. A., Anise, E. O., Obuotor, E. M., Samuel, T. A., Moshood, A., Olajide, M., & Fatoke, T. (2020) · Clinical Phytoscience · doi:10.1186/s40816-020-00236-2 · Cited by 35
Association between metformin use on admission and outcomes in intensive care unit patients with acute kidney injury and type 2 diabetes: A retrospective cohort study
Yang, Q., Zheng, J., Wen, D., Chen, X., Chen, W., Chen, W., Xiong, X.-M., & Zhang, Z. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.12.007 · Cited by 35
Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States
Cai, J. X., Divino, V. M., & Burudpakdee, C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1320277 · Cited by 35
Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
Kwon, C. S., Seoane-Vazquez, E. C., & Rodríguez-Monguió, R. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2860-0 · Cited by 37
Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
Kalra, S., Kesavadev, J., Chadha, M. D., & Kumar, G. V. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_162_17 · Cited by 35
Nanoscale dynamic chemical, biological sensor material designs for control monitoring and early detection of advanced diseases
El‐Safty, S. A., & Shenashen, M. A. (2020) · Materials Today Bio · doi:10.1016/j.mtbio.2020.100044 · Cited by 35
Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease
Roussel, R., Lorraine, J., Rodríguez, Á., & Salaun-Martin, C. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0261-x · Cited by 34
Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
Muskiet, M. H. A., van Bommel, E. J. M., & van Raalte, D. H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00457-x · Cited by 34
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Pearson, E. R., Dawed, A. Y., & Zhou, K. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s84854 · Cited by 34
Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection
Seo, Y.-S., Kim, Y.-J., Kim, M., Suh, K., Kim, S. B., Han, C. J., Kim, Y. J., Jang, W. I., Kang, S. H., Tchoe, H. J., et al. (2016) · Medicine · doi:10.1097/md.0000000000003527 · Cited by 34
Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype
Lim, L., Tan, A. T. B., Moses, K., Rajadhyaksha, V., & Chan, S. P. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.008 · Cited by 34
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
Evans, M., Chubb, B., & Gundgaard, J. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0236-9 · Cited by 34
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS
Engel, S. S., Suryawanshi, S., Stevens, S. R., Josse, R. G., Cornel, J. H., Jakubonienė, N., Riefflin, A., Tankova, T. I., Wainstein, J., Peterson, E. D., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12983 · Cited by 34
Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM)
Brož, J., Žďarská, D. J., Urbanová, J., Brabec, M., Doničová, V., Štěpánová, R., Martinka, E., & Kvapil, M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0485-2 · Cited by 34
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
Patorno, E., Najafzadeh, M., Pawar, A., Franklin, J. M., Déruaz‐Luyet, A., Brodovicz, K. G., Ortiz, A. J. S., Bessette, L. G., Kulldorff, M., & Schneeweiß, S. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.103 · Cited by 34
Clinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 34
Water‐Soluble Gold(III)–Metformin Complex Alters Mitochondrial Bioenergetics in Breast Cancer Cells
Kim, J. H., Ofori, S., Mertens, R. T., Parkin, S., & Awuah, S. G. (2021) · ChemMedChem · doi:10.1002/cmdc.202100233 · Cited by 34
Saxagliptin: A Review in Type 2 Diabetes
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0473-z · Cited by 34
Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
Bejan‐Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B. V., Audier, P., Brabant, Y., Gueyffier, F., & Boussageon, R. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.04.001 · Cited by 34
Management of diabetes in Indigenous communities: lessons from the Australian Aboriginal population
Nguyen, H. D., Chitturi, S., & Maple-Brown, L. J. (2016) · Internal Medicine Journal · doi:10.1111/imj.13123 · Cited by 34
The effects of liraglutide in mice with diet-induced obesity studied by metabolomics
Bugáňová, M., Pelantová, H., Holubová, M., Šedivá, B., Maletı́nská, L., Železná, B., Kuneš, J., Kačer, P., Kuzma, M., & Haluzı́k, M. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0478 · Cited by 34
Efficacy and safety of lixisenatide in a predominantly A sian population with type 2 diabetes insufficiently controlled with basal insulin: T he GetGoal‐L‐C randomized trial
Yang, W., Min, K. W., Zhou, Z., Li, L., Xu, X., Zhu, D., Rao, A. V., Murthy, L. S., Zhang, N., Li, I., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13072 · Cited by 34
Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification
Wang, T., Xi, Y., LUBWAMA, R. N., Hannanchi, H., Iglay, K., & Koro, C. E. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.026 · Cited by 34
Dendrocalamus latiflorus and its component rutin exhibit glucose-lowering activities by inhibiting hepatic glucose production via AKT activation
Luo, K., Huang, W., Qiao, L., Zhang, X., Yan, D., Ning, Z.-Y., Ma, C., Dang, H., Wang, D., Guo, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.017 · Cited by 33
Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ
Santos, J. C., Bernardes, A., Giampietro, L., Ammazzalorso, A., Filippis, B. D., Amoroso, R., & Polikarpov, I. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.07.006 · Cited by 33
Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., den Bos, I. C. P.-V., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 33
Self-citation
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Simultaneous Quantification of Antidiabetic Agents in Human Plasma by a UPLC–QToF-MS Method
Fachi, M. M., Cerqueira, L. B., Leonart, L. P., de Francisco, T. M. G., & Pontarolo, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167107 · Cited by 33
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up
Wilding, J. P. H., Bailey, C. J., Rigney, U., Blak, B. T., Kok, M. D., & Emmas, C. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.04.004 · Cited by 33
DPPH Radical Scavenging and Postprandial Hyperglycemia Inhibition Activities and Flavonoid Composition Analysis of Hawk Tea by UPLC-DAD and UPLC-Q/TOF MSE
Xiao, X., Xu, L., Hu, H.-G., Yang, Y., Zhang, X., Peng, Y., & Xiao, P. (2017) · Molecules · doi:10.3390/molecules22101622 · Cited by 33
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis
Sharma, R., Wilkinson, L., Vražić, H., Popoff, E., Lopes, S. H. K., Kanters, S., & Druyts, E. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1476332 · Cited by 33
Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.05.007 · Cited by 34
Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis
Qian, D., Zhang, T., Zheng, P., Liang, Z., Wang, S., Xie, J., Zhao, L., Zhang, Y., & Situ, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0482-5 · Cited by 33
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes
Henry, R. R., Frías, J. P., Walsh, B., Skare, S., Hemming, J., Burns, C. M., Bicsak, T. A., Baron, A., & Fineman, M. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203946 · Cited by 33
Postoperative Euglycaemic Diabetic Ketoacidosis Associated with Sodium–Glucose Cotransporter-2 Inhibitors (Gliflozins): A Report of Two Cases and Review of the Literature
Chacko, B., Whitley, M., Beckmann, U., Murray, K., & Rowley, M. (2018) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1804600212 · Cited by 33
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice
Hong, A. R., Koo, B. K., Kim, S. W., Yi, K. H., & Moon, M. K. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0134 · Cited by 33
Improving empowerment, motivation, and medical adherence in patients with poorly controlled type 2 diabetes: A randomized controlled trial of a patient-centered intervention
Varming, A. R., Rasmussen, L. B., Husted, G. R., Olesen, K., Grønnegaard, C., & Willaing, I. (2019) · Patient Education and Counseling · doi:10.1016/j.pec.2019.06.014 · Cited by 33
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE
Lee, A. K., Woodward, M., Wang, D., Ohkuma, T., Warren, B., Sharrett, A. R., Williams, B., Marre, M., Hamet, P., Harrap, S. B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz045 · Cited by 33
Syringaldehyde promoting intestinal motility with suppressing α-amylase hinders starch digestion in diabetic mice
Weng, L., Chen, T., Zheng, Q., Weng, W.-H., Huang, L., Lai, D., Fu, Y., & Weng, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111865 · Cited by 33
Metformin alleviates ionizing radiation-induced senescence by restoring BARD1-mediated DNA repair in human aortic endothelial cells
Park, J., Park, J., Kim, S.-R., Sim, M.-K., Kang, C., & Kim, K. S. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111706 · Cited by 33
Frailty in Diabetic Subjects during COVID-19 and Its Association with HbA1c, Mean Platelet Volume and Monocyte/Lymphocyte Ratio
Tel, B. M. A., Bilgin, S., Kurtkulağı, Ö., Kahveci, G. B., Duman, T. T., Sagdic, T., & Aktaş, G. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0015 · Cited by 33
The impact of peer coach-led type 2 diabetes mellitus interventions on glycaemic control and self-management outcomes: A systematic review and meta-analysis
Verma, I., Gopaldasani, V., Jain, V., Chauhan, S., Chawla, R., Verma, P. K., & Hosseinzadeh, H. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.10.007 · Cited by 33
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis
Zinman, B., Åhrén, B., Neubacher, D., Patel, S. D., Woerle, H., & Johansen, O. E. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.06.010 · Cited by 33
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( BEGIN : ADD TO GLP ‐1 S tudy)
Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L., Raskin, P., Zacho, J., Andersen, T. H., & Philis‐Tsimikas, A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12661 · Cited by 33
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review
Cimmaruta, D., Maiorino, M. I., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
A Test in Context
Gore, M. O., & McGuire, D. K. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.070 · Cited by 33

Authors: Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
Affiliations: Yale New Haven Hospital (US)
Park Nicollet Health Services (US)
University of North Carolina at Chapel Hill (US)
Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
University of Pisa (IT)
Diabeteszentrum Bad Lauterberg (DE)
University of Southern California (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
American Cancer Society (US)
Churchill Hospital (GB)
Corresponding author: Inzucchi, Silvio E.
ORCID: Inzucchi, Silvio E.
Bergenstal, Richard M.
Buse, John B.
Ferrannini, Ele
Nauck, Michael
Peters, Anne L.
Wender, Richard
Matthews, David R.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2014-12-13
Volume: 38
Issue: 1
Pages: 140-149
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc14-2441
OpenAlex: W2160088494
Cited by: 3,066
References: 68
Citations by year: 2026: 52 · 2025: 84 · 2024: 96 · 2023: 135 · 2022: 138 · 2021: 142 · 2020: 202 · 2019: 313 · 2018: 482 · 2017: 545 · 2016: 540 · 2015: 325 · 2014: 7
FWCI: 380.40
Type: journal article
Language: en
Open access: green
pure.amsterdamumc.nl
Licence: other-oa
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
GlaxoSmithKline
Sanofi
Massachusetts General Hospital
Yale University
Kaiser Permanente
F. Hoffmann-La Roche
Case Western Reserve University
School of Medicine, Case Western Reserve University
Intarcia Therapeutics
National Institute for Health and Care Research
University of Sydney
Universiteit van Amsterdam
University of Toronto
Novo Nordisk
Uniwersytet Łódzki
European Association for the Study of Diabetes
Université de Nantes
Servier
Lilly Deutschland
University of Ioannina
School of Medicine, University of Kansas
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: type 2 diabetes, hyperglycemia management, antidiabetic drugs, patient-centered care, shared decision-making, glucose-lowering agents, cardiovascular risk reduction, smoking cessation, blood pressure control, lipid control, statins, antiplatelet therapy, lifestyle modification
MeSH terms: Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hyperglycemia, Metformin, United States, Disease Management, Glycemic Index, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks